

Form PTO-1449 (modified)

Atty. Docket No.
AMBI:094USSerial No.
10/801,982

List of Patents and Publications for Applicant's

Applicant
Marianna Goldrick

INFORMATION DISCLOSURE STATEMENT

Filing Date:
March 16, 2004Group:
1653 1634

(Use several sheets if necessary)

U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
				X			

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
				X			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
u	C1	Alcorta <i>et al.</i> , "Microarray studies of gene expression in circulating leukocytes in kidney disease," <i>Exp Nephrol</i> , 10:139-149, 2002.
	C2	Alizadeh <i>et al.</i> , "Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling," <i>Nature</i> , 403:503-511, 2000.
	C3	Chomczynski P and Sacchi N., "Single-step method of RNA isolation by acid guanidinium phenol chloroform extraction," <i>Anal. Biochemistry</i> , 162:156-159, 1987.
	C4	Claes <i>et al.</i> , "Differentiating pathogenic mutations from polymorphic alterations in the splice sites for BRCA1 and BRCA2," <i>Genes Chromosomes Cancer</i> , 37:314-320, 2003.
	C5	Cummings CA and Relman DA., "Using DNA microarrays to study host-microbe interactions," <i>Emerg Infect Disease</i> , 6:513-525, 2000.
	C6	Duvigneau <i>et al.</i> , "Delay in processing porcine whole blood affects cytokine expression," <i>J Immunological Methods</i> , 272:11-21, 2003.
	C7	Ebner <i>et al.</i> , "Generation of large numbers of human dendritic cells from whole blood passaged through leukocyte removal filters: an alternative to standard buffy coats" <i>J. Immunol Methods</i> , 252:93-104 2001.
✓	C8	Grace <i>et al.</i> , "Real-time quantitative RT-PCR assay of GADD45 gene expression changes as a biomarker for radiation biodosimetry," <i>Int'l Journal of Radiation Biology</i> , 78:1011-21, 2002.

25418919.1

EXAMINER:

Subin

DATE CONSIDERED:

12/26/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. AMBI:094US	Serial No. 10/801,982
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Marianna Goldrick	
		Filing Date: March 16, 2004	Group: 1633 1634
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>u</i>	C9	Guhaniyogi J and Brewer G., "Regulation of mRNA stability in mammalian cells," <i>Gene</i> 265:11-23, 2001.
	C10	Härtel <i>et al.</i> , "Ex vivo induction of cytokine mRNA expression in human blood samples" <i>J Immunological Methods</i> , 249:63-71, 2001.
	C11	Haskill <i>et al.</i> , "Adherence induces selective mRNA expression of monocyte mediators and proto-oncogenes," <i>J Immunol.</i> , 140:1690-1694, 1988.
	C12	Hodge <i>et al.</i> , "IL-2 and IL-12 alter NK cell responsiveness to IFN-gamma-inducible protein 10 by down-regulating CXCR3 expression," <i>J Immunol.</i> , 168:6090-6098, 2002.
	C13	Kaufman, "Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line," <i>Cancer Res.</i> , 51:1129-1136, 1991.
	C14	Macfarlane DE and Dahle CE., "Isolating RNA from clinical samples with Catrimox-14 and lithium chloride," <i>J. Clin. Lab. Anal.</i> , 11:132-139, 1997.
	C15	Magalhaes <i>et al.</i> , "RNA synthesis inhibitors on young rat adrenal in primary culture. An ultrastructural study," <i>Tissue Cell</i> , 19:167-175, 1987.
	C16	Moenner <i>et al.</i> , "Secretion of ribonucleases by normal and immortalized cells grown in serum-free culture conditions," <i>In vitro Cell Dev. Biol. Anim.</i> , 33:553, 1997.
	C17	Pahl A and Brune K., "Stabilization of gene expression profiles in blood after phlebotomy," <i>Clinical Chemistry</i> , 48:2251-2253, 2002.
	C18	Raghavan <i>et al.</i> , "Genome-wide analysis of mRNA decay in resting and activated primary human T lymphocytes," <i>Nucleic Acid Res.</i> , 30:5529-5538, 2002.
	C19	Rainen <i>et al.</i> , "Stabilization of mRNA expression in whole blood samples," <i>Clinical Chemistry</i> , 48:1883-1890, 2002.
	C20	Ross <i>et al.</i> , "Classification of pediatric acute lymphoblastic leukemia by gene expression profiling," <i>Blood</i> , 102:2951-2959, 2002.
	C21	Scheuermann RH and Racila E., "CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy," <i>Leuk. Lymphoma</i> , 18:385-397, 1995.
↓	C22	Stahlberg <i>et al.</i> , "Quantitative real-time PCR method for detection of B-lymphocyte monoclonality by comparison of kappa and lambda immunoglobulin light chain expression," <i>Clinical Chemistry</i> , 49:51-59, 2003.

25418919.1

EXAMINER:

John M.

DATE CONSIDERED:

12/26/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. AMBI:094US	Serial No. 10/801,982
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Marianna Goldrick	
		Filing Date: March 16, 2004	Group: 1653 1634
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>m</i>	C23	Staudt and Brown, "Genomic views of the immune system," <i>Annual Review Immunology</i> , 18:829-859, 2000.
	C24	Stordeur <i>et al.</i> , "Analysis of spontaneous mRNA cytokine production in peripheral blood," <i>J Immunol Methods</i> , 261:195-197, 2002.
	C25	Tang <i>et al.</i> , "Blood genomic responses differ after stroke, seizures, hypoglycemia, and hypoxia: blood genomic fingerprints of disease," <i>Ann Neurol.</i> 50:699-707, 2001.
	C26	Theophilus, <i>RNA Isolation and Characterization Protocols</i> , pp 39-41, edit. R. Rapley and DL Manning, Humana Press, Totowa NJ, 1998
	C27	Verdeil <i>et al.</i> , "Gene profiling approach to establish the molecular basis for partial versus full activation of naïve CD8 T lymphocytes," <i>Ann NY Acad Sci.</i> , 975:68-76, 2002.
	C28	Weitkamp JH and Crowe JE., "Blood donor leukocyte reduction filters as a source of human B lymphocytes," <i>BioTechniques</i> , 31:464-466, 2001.
	C29	Whitney <i>et al.</i> , "Individuality and variation in gene expression patterns in human blood.," <i>Proc. Natl. Acad. Sci., USA</i> , 100:1896-1901, 2003.
	C30	Xiang <i>et al.</i> , "Probe generation directly from small numbers of cells for DNA microarray studies," <i>BioTechniques</i> , 34:386-393, 2003.
	C31	Yeoh, <i>et al.</i> , "Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling," <i>Cancer Cell March</i> , 133-143, 2002.
	C32	Zhu <i>et al.</i> , "Cellular gene expression altered by human cytomegalovirus: global monitoring with oligonucleotide arrays," <i>Proc. Natl. Acad. Sci., USA</i> , 95:14470-14475, 1998.
<i>✓</i>	C33	"Technical Note: Globin reduction protocol: a method for processing whole blood RNA samples for improved array results," <i>Gene Expression Monitoring</i> , Affymetrix Product Family, pp 1-9.

25418919.1

EXAMINER:

Sub m

DATE CONSIDERED:

12/26/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.
AMBI:094USSerial No.
10/801,982Applicant
Marianna GoldrickFiling Date:
March 16, 2004Group:
~~1653~~ 1634U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
<i>u</i>	A1	4,925,572	05/15/90	Pall	767	210	10/19/88

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
<i>u</i>	B1	WO 01/11362	02/15/01	WIPO	—	—	YES
<i>u</i>	B2	WO 94/17209	08/04/94	WIPO	—	—	YES

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>u</i>	C34	Hämäläinen <i>et al.</i> , "Major interference from leukocytes in reverse transcription-PCR identified as neurotoxin ribonuclease from eosinophils: detection of residual chronic myelogenous leukemia from cell lysates by use of an eosinophil-depleted cell preparation", <i>Clinical Chemistry</i> , 45: 465-471, 1999.

25617987.1

EXAMINER:

Perk u

DATE CONSIDERED:

12/26/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)